What is New in Hormone Therapy for Prostate Cancer in 2007? Bertrand Tombal  European Urology Supplements  Volume 7, Issue 6, Pages 477-483 (April 2008) DOI: 10.1016/j.eursup.2008.01.002 Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 1 Outcomes of the voting on the question: “Which of these indications is not an evidence-based recognised indication of androgen deprivation therapy?” Answer 1: Immediate treatment of symptomatic patients. Answer 2: Long life adjuvant treatment of patients with positive lymph nodes at radical prostatectomy. Answer 3: Short-term (6 mo) adjuvant treatment to external-beam radiation therapy (EBRT) in patients with locally advanced rapidly progressing prostate cancer. Answer 4: Long-term (3 yr) adjuvant treatment of patients with positive margins and seminal vesicle invasion after radical prostatectomy. European Urology Supplements 2008 7, 477-483DOI: (10.1016/j.eursup.2008.01.002) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 2 Recurrences, overall death, and prostate cancer (PCa)-specific death at a median follow-up of 11.9 yr in patients who received immediate androgen-deprivation therapy (ADT; n=47) versus deferred ADT (n=51) because of positive lymph nodes after radical prostatectomy and pelvic lymphadenectomy [10]. European Urology Supplements 2008 7, 477-483DOI: (10.1016/j.eursup.2008.01.002) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 3 General perceptions about the impact of prostate cancer (PCa) on health status after primary androgen-deprivation therapy by means of luteinising hormone-releasing hormone (LHRH) agonists (n=299) or orchidectomy (n=132) [16]. European Urology Supplements 2008 7, 477-483DOI: (10.1016/j.eursup.2008.01.002) Copyright © 2008 European Association of Urology Terms and Conditions